Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of Prostate-Specific Membrane Antigen and Hypoxia for Prostate Cancer
- 28 November 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 30 (1) , 90-100
Abstract
Prostate cancer is one of the most common cancers in the world. It is widely known that prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, and hypoxia is a common characteristic of many solid tumors, including prostate cancer. In this study, we designed multifunctional fluorescent inhibitors to target PSMA and tumor hypoxia in order to increase the tumor uptake of inhibitors. Novel PSMA inhibitors were prepared using lysine as the backbone to connect three different functional groups: the glutamate-urea-lysine (GUL) structure for inhibiting PSMA, 2-nitroimidazole for the hypoxia-sensitive moiety, and a near-infrared fluorophore (sulfo-Cyanine 5.5). According to the in vitro PSMA binding assay, novel fluorescent inhibitors were demonstrated to have nanomolar binding affinities. Multifunctional inhibitor 2 with one 2-nitroimidazole had a similar inhibitory activity to inhibitor 1 that did not contain the hypoxia targeting moiety, but multifunctional inhibitor 3 with two 2-nitroimidazoles showed lower inhibitory activity than inhibitor 1 due to the bulky structure of the hypoxia-sensitive group. However, in vivo optical imaging and ex vivo biodistribution studies indicated that both multifunctional inhibitors 2 and 3 had higher accumulation in tumors than inhibitor 1 due to a synergistic combination of PSMA and hypoxia targeting moieties. These observations suggest that this novel multifunctional strategy might be a promising approach to improve the diagnosis and therapy of prostate cancer.Keywords
Funding Information
- National Research Foundation of Korea (2018R1D1A1B07047572)
- Biomedical Research Institute, Chonbuk National University Hospital
This publication has 40 references indexed in Scilit:
- A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancerEJNMMI Research, 2012
- Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate CancerClinical Cancer Research, 2012
- Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigenBioorganic & Medicinal Chemistry Letters, 2011
- Synthesis and evaluation of two novel 2-nitroimidazole derivatives as potential PET radioligands for tumor imagingNuclear Medicine and Biology, 2011
- A low molecular weight PSMA-based fluorescent imaging agent for cancerBiochemical and Biophysical Research Communications, 2009
- Assessment of an 18F-Labeled Phosphoramidate Peptidomimetic as a New Prostate-Specific Membrane Antigen–Targeted Imaging Agent for Prostate CancerJournal of Nuclear Medicine, 2009
- Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate CancerJournal of Medicinal Chemistry, 2008
- Near-Infrared Fluorescent Deoxyglucose Analogue for Tumor Optical Imaging in Cell Culture and Living MiceBioconjugate Chemistry, 2006
- Nitroimidazoles and imaging hypoxiaEuropean Journal of Nuclear Medicine and Molecular Imaging, 1995
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973